Introduction
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data.
In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 22 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for NSCLC and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).
Example of drugs included in this study
Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474,
Example of companies included in this study
Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik
Scope of this report
Thorough examination of status and impact of many novel drugs in development
Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Case studies on major lung cancer drugs on market and in development.
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development.
- Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
- Gain insight into the current challenges and commercial opportunities associated with lung cancer
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 4.1 List of boxes
4.2 List of tables
4.3 Appendices
5 Introduction
5.1 Current Treatment Strategies
5.2 Disease Definition
5.3 Etiology & Pathophysiology
5.4 Prognosis
5.5 Epidemiology
6 Progress in current treatment strategies
6.1 Docetaxel
6.2 Vinorelbine
6.3 Gemcitabine
6.4 Paclitaxel
6.5 Pemetrexed
6.6 Gefitinib
6.7 Erlotinib
6.8 Bevacizumab
7 Key Therapeutic Strategies
7.1 Apoptosis
7.2 Protein Kinase Inhibition - Antiangiogenesis and Antivascular Agents
7.2.1 EGFR and VEGFR as target
7.3 Immunotherapy
8 Competitive Landscape in NSCLC Drug Development: The Late Stage Pipeline
8.1 Protein Kinase Inhibitors
8.2 Apoptotic Inducers
8.3 Immunotherapy
8.4 Other Therapeutic Strategies
9 Disclaimer
9.1 Liability
9.2 Completeness
10 Appendix 1. Treatment Guide Lines
11 Appendix 2 Progress Profiles on Approved Drugs
11.1 Docetaxel
11.2 Vinorelbine
11.3 Gemcitabine
11.4 Paclitaxel
11.5 Pemetrexed
11.6 Gefitinib
11.7 Erlotinib
12 Drug Index
13 Company Index
4.1 List of boxes
Box 1: Quick Facts - Docetaxel
Box 2: Scientific Data on Docetaxel
Box 3: Quick Facts - Vinorelbine
Box 4: Scientific Data on Vinorelbine
Box 5: Quick Facts - Gemcitabine
Box 6: Scientific Data on gemcitabine
Box 7: The PIONEER clinical trial
Box 8: Quick Facts - Pemetrexed
Box 9: Scientific Data on Pemetrexed
Box 10: Quick Facts - Gefitinib
Box 11: Scientific Data on Gefitinib
Box 12: Expert comment
Box 13: Quick Facts - Erlotinib
4.2 List of tables
Table 1: Chemotherapeutic Drugs for Treatment of NSCLC
Table 2: Clinical Studies of NSCLC Patients With EGFR Mutations
Table 3 Progress on Bevacizumab
Table 4. Near Term Approved Drugs for the Treatment of NSCLC
Table 5: Chemotherapy Drugs off Patent
Table 6 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Table 7 VTA Agents Under Development
Table 8 EGFR or VEGFR Inhibitors
Table 9: FMS-Like Tyrosine Kinases and Their Synonyms
Table 10: Fms-related Tyrosine Kinase Targets in Development
Table 11: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 12 Cancer Immunotherapy Strategies
Table 13 Progress on Lapatinib
Table 14 Progress on ZD6474
Table 15: Progress on Trastuzumab
Table 16 Progress on Panitumumab
Table 17 Progress on Cetuximab
Table 18: Progress on Neovastat
Table 19: Progress on Affinitak
Table 20: Progress on Sorafenib
Table 21: Progress on Canfosfamide
Table 22: Progress on Exisulind
Table 23 Progress on Genasense
Table 24 Progress on Bexarotene
Table 25: Progress on IGN101
Table 26: Progress on CPG 7909
Table 27 Progress on Vinflunine
Table 28: Progress on Talabostat
Table 29: Ongoing Studies
Table 30 Progress on Xcytrin
Table 31: Progress on Tirapazamine
Table 32: Progress on Efaproxiral
4.3 Appendices
10 Appendix 1. Treatment Guide Lines
11 Appendix 2 Progress Profiles on Approved Drugs
- Aphton
- AstraZeneca
- Bristol-Myers Squibb
- Cell Pathways
- Eli Lilly
- Genentech
- Genta
- GlaxoSmithKline
- ImClone
- ISIS Pharmaceuticals
- Ligand Pharmaceuticals
- OSI Pharmaceuticals
- Pfizer
- Pharmacyclics
- Sanofi-Aventis
- Telik
Other selected research from the 'Cancer Highlights' category:
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Other selected research from the 'Oncology' category:
Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors